20180629 Nordea Markets - Saniona

Klaria Pharma Hold. Forum Placera

The technology company earned $9.92 million during the quarter, compared to analysts' expectations of $9.30 million. SANTA MONICA, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is Opiant Pharmaceuticals posted sales of $4.28 million during the same quarter last year, which would indicate a positive year over year growth rate of 28%. The company is expected to announce its next quarterly earnings results on Tuesday, May 11th.

1. Varför dog tobias
2. Göteborgs bussar
3. Juristprogrammet behorighet
4. Uppskjutet offentliggörande finansinspektionen
5. Låt som legat längst på svensktoppen
6. Specialpedagog
7. Moodle psgtech
8. Svenska till hebreiska

We are headquartered in Santa Monica, with additional offices in London, UK. We were founded in 2009. In 2013, Opiant developed the first FDA-approved, user-friendly nasal naloxone spray. Opiant Pharmaceuticals (NASDAQ OPNT) News Headlines Today Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Get the latest Opiant Pharmaceuticals (OPNT) stock price quote with real-time news, financials, charts and other important investing information. 2021-03-22 · Opiant Pharmaceuticals, Inc., the company that developed NARCAN ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com .

Trump till kamp mot opiatberoende Placera - Avanza

Enjoy the benefits at Opiant. Because our people are our greatest asset, we want to take care of our people.

Orexo: Betydelsefull framgång i klinisk studie - Redeye

10.61 0.03 (0.28%) Upgrade to Real-Time Regular Market . Proxy Statement - Merger or Acquistion (preliminary) (prem14a) Opiant is a pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose.

For more information visit 2021-03-31 · Opiant Pharmaceuticals, Inc., the company that developed NARCAN ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information, visit Find the latest Opiant Pharmaceuticals, Inc. (OPNT) stock quote, history, news and other vital information to help you with your stock trading and investing. 2021-04-13 · OPNT Opiant Pharmaceuticals Inc Current Report Filing (8-k) On April 12, 2021, the Board of Directors (the “Board”) of Opiant Pharmaceuticals, Inc. (the “Company”) adopted stock ownership guidelines for the Company’s non-employee directors and executive officers to help ensure that they each maintain an equity stake in the Company and, by doing so, appropriately link their interests 2021-03-04 · Wall Street analysts have given Opiant Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains.
Nanna svartz gata västerås

, March 31, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions… Opiant Pharmaceuticals News Headlines $10.50-0.29 (-2.69 %) (As of 04/7/2021 12:00 AM ET) Add. Compare.

For more information, visit Find the latest Opiant Pharmaceuticals, Inc. (OPNT) stock quote, history, news and other vital information to help you with your stock trading and investing. 2021-04-13 · OPNT Opiant Pharmaceuticals Inc Current Report Filing (8-k) On April 12, 2021, the Board of Directors (the “Board”) of Opiant Pharmaceuticals, Inc. (the “Company”) adopted stock ownership guidelines for the Company’s non-employee directors and executive officers to help ensure that they each maintain an equity stake in the Company and, by doing so, appropriately link their interests 2021-03-04 · Wall Street analysts have given Opiant Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market.
Kristinehamn kommun utbildning

dan olsson bygg höganäs
jus stockholm shop
crema batida
angular webshop demo
wermlandsflyg jobb

• urr
• QzXs
• mkFI
• GSp
• Dw
• rZnO
• QWD

• Mats persson folkpartiet
• Nicolin
• Hur fungerar nya karensavdraget
• Angiolipoma pictures
• Är flyget i tid kiruna
• Leimert park
• En ledares bästa egenskaper
• Medicinsk teknik bok
• Anders bibliotek
• Hemnet vänersborg

20180629 Nordea Markets - Saniona

Adapt Pharma som licensierar produkten från Opiant Pharmaceuticals, fanns med på mötet. 17 maj 2018 — Oasmia Pharmaceutical AB kommer att presentera uppföljande resultat från den genomförda fas III-studien med Apealea® för behandling av  Opiant, som är ett litet bolag med ett marknadsvärde på cirka 400 miljoner kronor, steg med 28 procent under börshandeln, rapporterar Bloomberg News. 20 mars 2018 — Detta rapporterar Reuters och Bloomberg News. Adapt Pharma som licensierar produkten från Opiant Pharmaceuticals, fanns med på mötet. 7 jan. 2019 — av Narcan bedöms överstiga 200 MUSD (Opiant Pharmaceuticals).

# LÄKEMEDEL: TRUMP TRAPPAR UPP OPIATKAMPEN

Adapt Pharma som licensierar produkten från Opiant Pharmaceuticals, fanns med på mötet. 17 maj 2018 — Oasmia Pharmaceutical AB kommer att presentera uppföljande resultat från den genomförda fas III-studien med Apealea® för behandling av  Opiant, som är ett litet bolag med ett marknadsvärde på cirka 400 miljoner kronor, steg med 28 procent under börshandeln, rapporterar Bloomberg News. 20 mars 2018 — Detta rapporterar Reuters och Bloomberg News. Adapt Pharma som licensierar produkten från Opiant Pharmaceuticals, fanns med på mötet.

NetworkNewsBreaks – Pressure BioSciences, Inc. (PBIO) Technology Helps Opiant Pharmaceuticals, Inc. Announces Additional $3.75 Million Payment From​  Opiant Pharmaceuticals, the company that invented the Narcan spray, opioid addiction on WJXT Jacksonville Action 4 News #wjxt4news #opioidaddiction #  20 mars 2018 — Detta rapporterar Reuters och Bloomberg News. Adapt Pharma som licensierar produkten från Opiant Pharmaceuticals, fanns med på mötet. 20 mars 2018 — Detta rapporterar Reuters och Bloomberg News. Adapt Pharma som licensierar produkten från Opiant Pharmaceuticals, fanns med på mötet. 17 maj 2018 — Oasmia Pharmaceutical AB kommer att presentera uppföljande resultat från den genomförda fas III-studien med Apealea® för behandling av  Opiant, som är ett litet bolag med ett marknadsvärde på cirka 400 miljoner kronor, steg med 28 procent under börshandeln, rapporterar Bloomberg News. 20 mars 2018 — Detta rapporterar Reuters och Bloomberg News.